Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

<p>BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that the European Medicines Agency (EMA) has issued a positive opinion on the […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/rhythm-pharmaceuticals-receives-orphan-drug-designation-from-european-medicines-agency-for-setmelanotide-for-treatment-of-acquired-hypothalamic-obesity/">Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>